Praxis Precision Medicines Inc
PRAX
Get informed when a big investor buys or sells
+ FollowMarket Cap$7.4B
Close$
$15.87
94.3% downside
Current Fair Value
94.3% downsideOvervalued by 94.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $7.40 Billion |
|---|---|
| Enterprise Value | $6.86 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-13.48 |
| Beta | 2.78 |
| Outstanding Shares | 28,883,596 |
Return
| Return on Equity | -23.16% |
|---|---|
| Return on Assets | -22.36% |
| Return on Invested Capital | -25.31% |
Valuation & Multiples
| P/E Ratio | -30.96 |
|---|---|
| PEG | -92.21 |
| Price to Sales | - |
| Price to Book Ratio | 5.81 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -19.24 |
| Enterprise Value to Net Income | -22 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 13, 2026
EPS Estimate
$-3.60
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 3, 2026
EPS Estimate
$-3.67
Average shareholder expectationRevenue Estimate
$1.25 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 3.6084▲ 254.53% |
|---|---|
| Total Calls | 157,300▼ 78.83% |
| Total Puts | 567,600▼ 28.15% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 141.26%▲ 7.17% |
|---|---|
| Total Invested | $10.24B▲ 17.84% |
| Investors Holding | 307▲ 35.00% |
ESG Score
No data
About Praxis Precision Medicines Inc
2,020 employeesPraxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders (CNS) characterized by neuronal imbalance. Praxis is applying in...